Cassava Sciences | PTIE - Cost Of Sales


Cassava Sciences reported $3.96M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Geron USD 1.31M 263K Dec/2025
J&J USD 8.07B 103M Mar/2026
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025